SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Company Response from Forte Biosciences, Inc. (FBRX) (CIK 0001419041) (FBRX) — Sep 6, 2023

Forte Biosciences, Inc. (FBRX) (CIK 0001419041)
Date: Sept. 6, 2023 · CIK: 0001419041 · Accession: 0001193125-23-229577

Offering / Registration Process Regulatory Compliance Business Model Clarity

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-274257

Date
September 6, 2023
Author
Paul A. Wagner, Ph.D.
Form
CORRESP
Company
Forte Biosciences, Inc. (FBRX) (CIK 0001419041)

Letter

September 6, 2023

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549-3720

Attn: Daniel Crawford

Re: Forte Biosciences, Inc.

Registration Statement on Form S-3

File No. 333-274257

Acceleration Request

Requested Date: September 8, 2023

Requested Time: 4:00 P.M. Eastern Time

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Forte Biosciences, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-3 (File No. 333-274257) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Dan Koeppen at (858) 350-2393 or via email at dkoeppen@wsgr.com.

Sincerely,
FORTE BIOSCIENCES, INC.

Show Raw Text
CORRESP
1
filename1.htm

CORRESP

 September 6, 2023

VIA EDGAR

 U.S. Securities and Exchange Commission

Division of Corporation Finance

 Office of Life Sciences

100 F Street, N.E.

 Washington, D.C. 20549-3720

Attn: Daniel Crawford

Re:
 Forte Biosciences, Inc.

Registration Statement on Form S-3

File No. 333-274257

Acceleration Request

Requested Date: September 8, 2023

Requested Time: 4:00 P.M. Eastern Time

Ladies and Gentlemen:

 Pursuant to Rule 461 under the Securities
Act of 1933, as amended, Forte Biosciences, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-3 (File
No. 333-274257) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above, or at such later time as the Company
or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please confirm that event with our
counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Dan Koeppen at (858) 350-2393 or via email at dkoeppen@wsgr.com.

Sincerely,

FORTE BIOSCIENCES, INC.

 /s/ Paul A. Wagner, Ph.D.

Paul A. Wagner, Ph.D.

Chief Executive Officer

cc:
 Dan Koeppen, Wilson Sonsini Goodrich & Rosati, P.C.